K43TW012839
Project Grant
Overview
Grant Description
Integrating tuberculosis treatment into community pharmacies to improve TB/HIV outcomes in Uganda.
- Project summary/abstract
The overall objective of this K43 Emerging Global Leader Award is to support Dr. Jonathan Izudi’s transition to independence as an implementation scientist focused on improving tuberculosis (TB)/HIV care.
Dr. Izudi's long-term goal is to reduce the TB burden among people living with HIV (PLHIV) by tackling barriers to successful prevention, diagnosis, and treatment using context-relevant interventions delivered through person-centered strategies.
The overall objective of this K43 grant application is to develop and pilot an implementation strategy focused on integrating TB treatment into community pharmacies among people with TB/HIV in Uganda.
People with TB/HIV have sub-optimal treatment outcomes, with the pooled treatment success rate averaging 70-71%, far below the World Health Organization's desired target of ≥90%.
Compared to people who do not have HIV, treatment success is 35-47% lower and the risk of developing multi-drug resistant TB is 24% higher.
Community pharmacies are a proven differentiated antiretroviral therapy (ART) service delivery model that has been successful in moving ART from central health facilities to the community.
In doing so, ART access, coverage, and adherence are improved because medication pick-ups are more convenient, inadvertent HIV status disclosure and community stigma are prevented, and health workers can focus on people with adherence challenges.
Community pharmacies present a potential to provide similar benefits to people with TB/HIV through offering TB medication refills.
Dr. Izudi hypothesizes that a theory-informed, context-relevant strategy for integrating TB treatment into community pharmacies adapted to the needs of people with TB/HIV and health workers will improve TB treatment success.
To test the central hypothesis, Dr. Izudi proposed three specific aims:
Aim 1) To explore the barriers and facilitators to integrating TB treatment into community pharmacies among people with TB/HIV;
Aim 2) To adapt a person-centered strategy for integrating TB treatment into community pharmacies using human-centered design methodology; and,
Aim 3) To evaluate the implementation outcomes (feasibility, fidelity, and acceptability) and preliminary effectiveness of integrating TB treatment into community pharmacies among people with TB/HIV.
Completion of the aims will provide the preliminary data to support Dr. Izudi's application for an R01 proposing a cluster-randomized trial to evaluate the implementation and effectiveness of integrating TB treatment into community pharmacies at the national level.
In addition, conducting the proposed studies will enable Dr. Izudi to achieve four training goals:
1) To acquire advanced skills in qualitative and mixed methods research;
2) To gain skills and competence in implementation science research enabling the sound use of theories, models, and frameworks;
3) To gain expertise in interventional studies in implementation science research; and
4) To gain expertise in grantsmanship for transition to a successful research career.
The proposed studies will enable Dr. Izudi to complement his skillset in public health and epidemiology with advanced skills in socio-behavioral research, implementation science, and interventional studies through specific training and tailored mentorship.
- Project summary/abstract
The overall objective of this K43 Emerging Global Leader Award is to support Dr. Jonathan Izudi’s transition to independence as an implementation scientist focused on improving tuberculosis (TB)/HIV care.
Dr. Izudi's long-term goal is to reduce the TB burden among people living with HIV (PLHIV) by tackling barriers to successful prevention, diagnosis, and treatment using context-relevant interventions delivered through person-centered strategies.
The overall objective of this K43 grant application is to develop and pilot an implementation strategy focused on integrating TB treatment into community pharmacies among people with TB/HIV in Uganda.
People with TB/HIV have sub-optimal treatment outcomes, with the pooled treatment success rate averaging 70-71%, far below the World Health Organization's desired target of ≥90%.
Compared to people who do not have HIV, treatment success is 35-47% lower and the risk of developing multi-drug resistant TB is 24% higher.
Community pharmacies are a proven differentiated antiretroviral therapy (ART) service delivery model that has been successful in moving ART from central health facilities to the community.
In doing so, ART access, coverage, and adherence are improved because medication pick-ups are more convenient, inadvertent HIV status disclosure and community stigma are prevented, and health workers can focus on people with adherence challenges.
Community pharmacies present a potential to provide similar benefits to people with TB/HIV through offering TB medication refills.
Dr. Izudi hypothesizes that a theory-informed, context-relevant strategy for integrating TB treatment into community pharmacies adapted to the needs of people with TB/HIV and health workers will improve TB treatment success.
To test the central hypothesis, Dr. Izudi proposed three specific aims:
Aim 1) To explore the barriers and facilitators to integrating TB treatment into community pharmacies among people with TB/HIV;
Aim 2) To adapt a person-centered strategy for integrating TB treatment into community pharmacies using human-centered design methodology; and,
Aim 3) To evaluate the implementation outcomes (feasibility, fidelity, and acceptability) and preliminary effectiveness of integrating TB treatment into community pharmacies among people with TB/HIV.
Completion of the aims will provide the preliminary data to support Dr. Izudi's application for an R01 proposing a cluster-randomized trial to evaluate the implementation and effectiveness of integrating TB treatment into community pharmacies at the national level.
In addition, conducting the proposed studies will enable Dr. Izudi to achieve four training goals:
1) To acquire advanced skills in qualitative and mixed methods research;
2) To gain skills and competence in implementation science research enabling the sound use of theories, models, and frameworks;
3) To gain expertise in interventional studies in implementation science research; and
4) To gain expertise in grantsmanship for transition to a successful research career.
The proposed studies will enable Dr. Izudi to complement his skillset in public health and epidemiology with advanced skills in socio-behavioral research, implementation science, and interventional studies through specific training and tailored mentorship.
Funding Goals
THE JOHN E. FOGARTY INTERNATIONAL CENTER (FIC) SUPPORTS RESEARCH AND RESEARCH TRAINING TO REDUCE DISPARITIES IN GLOBAL HEALTH AND TO FOSTER PARTNERSHIPS BETWEEN U.S. SCIENTISTS AND THEIR COUNTERPARTS ABROAD. FIC SUPPORTS BASIC BIOLOGICAL, BEHAVIORAL, AND SOCIAL SCIENCE RESEARCH, AS WELL AS RELATED RESEARCH TRAINING AND CAREER DEVELOPMENT. THE RESEARCH PORTFOLIO IS DIVIDED INTO SEVERAL PROGRAMS THAT SUPPORT A WIDE VARIETY OF FUNDING MECHANISMS TO MEET PROGRAMMATIC OBJECTIVES.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Uganda
Geographic Scope
Foreign
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 100% from $109,704 to $219,556.
The Infectious Diseases Institute was awarded
TB/HIV Integration in Community Pharmacies Improved Outcomes in Uganda
Project Grant K43TW012839
worth $219,556
from Fogarty International Center in September 2024 with work to be completed primarily in Uganda.
The grant
has a duration of 5 years and
was awarded through assistance program 93.989 International Research and Research Training.
The Project Grant was awarded through grant opportunity Emerging Global Leader Award (K43 Independent Clinical Trial Required).
Status
(Ongoing)
Last Modified 8/20/25
Period of Performance
9/1/24
Start Date
8/31/29
End Date
Funding Split
$219.6K
Federal Obligation
$0.0
Non-Federal Obligation
$219.6K
Total Obligated
Activity Timeline
Transaction History
Modifications to K43TW012839
Additional Detail
Award ID FAIN
K43TW012839
SAI Number
K43TW012839-1061498975
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Non-Domestic (Non-U.S.) Entity
Awarding Office
75NF00 NIH Fogarty International Center
Funding Office
75NF00 NIH Fogarty International Center
Awardee UEI
THLMFMXSXTC4
Awardee CAGE
SCX13
Performance District
Not Applicable
Modified: 8/20/25